136.92 USD
-5.42 (-3.81%)
136.92 USD
0 (0%)
Taking everything into account, NUTX scores 6 out of 10 in our fundamental rating. NUTX was compared to 100 industry peers in the Health Care Providers & Services industry. NUTX has an excellent financial health rating, but there are some minor concerns on its profitability. NUTX is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, NUTX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
NUTX had positive earnings in the past year.
In the past year NUTX had a positive cash flow from operations.
In the past 5 years NUTX reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NUTX reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.82%, NUTX belongs to the top of the industry, outperforming 93.00% of the companies in the same industry.
NUTX has a Return On Equity of 34.08%. This is amongst the best in the industry. NUTX outperforms 96.00% of its industry peers.
NUTX has a Return On Invested Capital of 30.54%. This is amongst the best in the industry. NUTX outperforms 99.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROIC | 30.54% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NUTX has a Profit Margin of 10.76%. This is amongst the best in the industry. NUTX outperforms 93.00% of its industry peers.
NUTX's Operating Margin of 33.39% is amongst the best of the industry. NUTX outperforms 99.00% of its industry peers.
Looking at the Gross Margin, with a value of 48.77%, NUTX is in the better half of the industry, outperforming 74.00% of the companies in the same industry.
In the last couple of years the Gross Margin of NUTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
NUTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for NUTX has been reduced compared to 1 year ago.
NUTX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NUTX has been reduced compared to a year ago.
2.2 Solvency
NUTX has an Altman-Z score of 2.29. This is not the best score and indicates that NUTX is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.29, NUTX perfoms like the industry average, outperforming 54.00% of the companies in the same industry.
The Debt to FCF ratio of NUTX is 4.45, which is a neutral value as it means it would take NUTX, 4.45 years of fcf income to pay off all of its debts.
NUTX has a better Debt to FCF ratio (4.45) than 70.00% of its industry peers.
A Debt/Equity ratio of 1.46 is on the high side and indicates that NUTX has dependencies on debt financing.
NUTX has a Debt to Equity ratio of 1.46. This is in the lower half of the industry: NUTX underperforms 69.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 2.29 |
ROIC/WACC3.84
WACC7.96%
2.3 Liquidity
NUTX has a Current Ratio of 2.27. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
NUTX has a Current ratio of 2.27. This is amongst the best in the industry. NUTX outperforms 81.00% of its industry peers.
A Quick Ratio of 2.26 indicates that NUTX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.26, NUTX belongs to the best of the industry, outperforming 81.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 430.28% over the past year.
The Revenue has grown by 141.25% in the past year. This is a very strong growth!
Measured over the past years, NUTX shows a very strong growth in Revenue. The Revenue has been growing by 222.96% on average per year.
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
3.2 Future
NUTX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.02% yearly.
NUTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 72.84% yearly.
EPS Next Y-60.63%
EPS Next 2Y-22.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year186.75%
Revenue Next 2Y72.84%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.52 indicates a reasonable valuation of NUTX.
Based on the Price/Earnings ratio, NUTX is valued cheaper than 86.00% of the companies in the same industry.
NUTX is valuated cheaply when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 25.79, which means the current valuation is very expensive for NUTX.
The rest of the industry has a similar Price/Forward Earnings ratio as NUTX.
When comparing the Price/Forward Earnings ratio of NUTX to the average of the S&P500 Index (34.46), we can say NUTX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.52 | ||
| Fwd PE | 25.79 |
4.2 Price Multiples
NUTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NUTX is cheaper than 95.00% of the companies in the same industry.
NUTX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. NUTX is cheaper than 79.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.96 | ||
| EV/EBITDA | 4.42 |
4.3 Compensation for Growth
NUTX has a very decent profitability rating, which may justify a higher PE ratio.
NUTX's earnings are expected to decrease with -22.02% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.02%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
136.92
-5.42 (-3.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners32.21%
Inst Owner Change38.58%
Ins Owners3.03%
Ins Owner Change0%
Market Cap761.28M
Revenue(TTM)624.28M
Net Income(TTM)67.18M
Analysts82.22
Price Target246.5 (80.03%)
Short Float %23.49%
Short Ratio6.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP19.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4474.63%
Min EPS beat(2)9.6%
Max EPS beat(2)8939.67%
EPS beat(4)3
Avg EPS beat(4)2105.75%
Min EPS beat(4)-602.61%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)143.87%
Min Revenue beat(2)76.42%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)75.65%
Min Revenue beat(4)5.5%
Max Revenue beat(4)211.33%
Revenue beat(8)5
Avg Revenue beat(8)36.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-81.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-56.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)25.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.52 | ||
| Fwd PE | 25.79 | ||
| P/S | 1.22 | ||
| P/FCF | 10.96 | ||
| P/OCF | 10.71 | ||
| P/B | 3.86 | ||
| P/tB | 4.53 | ||
| EV/EBITDA | 4.42 |
EPS(TTM)11.89
EY8.68%
EPS(NY)5.31
Fwd EY3.88%
FCF(TTM)12.49
FCFY9.12%
OCF(TTM)12.78
OCFY9.34%
SpS112.28
BVpS35.45
TBVpS30.21
PEG (NY)N/A
PEG (5Y)N/A
Graham Number97.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROCE | 35.61% | ||
| ROIC | 30.54% | ||
| ROICexc | 35.64% | ||
| ROICexgc | 37.81% | ||
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% | ||
| FCFM | 11.12% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 8.22% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 59.03 | ||
| Cash Conversion | 31.12% | ||
| Profit Quality | 103.36% | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.29 |
F-Score8
WACC7.96%
ROIC/WACC3.84
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
EPS Next Y-60.63%
EPS Next 2Y-22.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
Revenue Next Year186.75%
Revenue Next 2Y72.84%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4652.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year951.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y98.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.51%
OCF growth 3YN/A
OCF growth 5YN/A
NUTEX HEALTH INC / NUTX FAQ
What is the ChartMill fundamental rating of NUTEX HEALTH INC (NUTX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to NUTX.
What is the valuation status for NUTX stock?
ChartMill assigns a valuation rating of 5 / 10 to NUTEX HEALTH INC (NUTX). This can be considered as Fairly Valued.
What is the profitability of NUTX stock?
NUTEX HEALTH INC (NUTX) has a profitability rating of 6 / 10.
What is the expected EPS growth for NUTEX HEALTH INC (NUTX) stock?
The Earnings per Share (EPS) of NUTEX HEALTH INC (NUTX) is expected to decline by -60.63% in the next year.
Can you provide the dividend sustainability for NUTX stock?
The dividend rating of NUTEX HEALTH INC (NUTX) is 0 / 10 and the dividend payout ratio is 19.83%.